Pharmaceuticals News & Press Release Distribution

Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

* New data on COVID-19 Influenza combination vaccine and seasonal influenza vaccine to be presented at World Vaccine Congress * Several abstracts and presentations slated to highlight updates on NVX-CoV2373, Novavax' COVID-19 vaccine GAITHERSBURG, Md., April 18, 2022 /PRNewswire/ -- Novavax...

2022-04-18 22:13 3200

WHO report highlights the role of Traditional Chinese Medicine in the treatment of COVID-19

BEIJING, April 18, 2022 /PRNewswire/ -- A news report by haiwainet.cn: On March 31, World Health Organization released the meeting report of "WHO Expert Meeting on Evaluation of Traditional Chinese Medicine (TCM) in the Treatment of COVID-19" on its official website. The report acknowledged that ...

2022-04-18 15:18 2043

Illumina Singapore Jumps the Ranks to Earn Two Significant Spots in Singapore's Best Employers Award

The Annual Singapore's Best Employers survey is sponsored by The Straits Times and marketing firm, Statista. SINGAPORE, April 18, 2022 /PRNewswire/ -- Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) was honoured today to be ranked #17 overall and #1 in Healthcare Equipment & Servic...

2022-04-18 12:00 2992

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021 annual report today. The company is currently making steady progress in mu...

2022-04-14 22:49 2349

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Pre-clinical & clinical exploratory poster presentations to highlight oncology results with Debio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates LAUSANNE, Switzerland, April 14, 2022 /PRNewswire/ -- Debiopharm, ( www.debiopharm.com/debiopharm-international/

2022-04-14 21:20 2699

CDD Vault Integrates with SnapGene Server for Web-Based Sharing of Plasmid Information

BURLINGAME, Calif. and SAN DIEGO, April 14, 2022 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD) announced today that it has completed the integration of SnapGene Server with its flagshipCDD Vault research informatics platform. This integration allows users to visualize and share plasmid...

2022-04-14 20:45 2403

China Medical System (0867.HK): the Leader in Commercialization Embraces Great Industry Opportunities as Biotech Companies are Eager to Monetize Their Innovative Products

HONG KONG, April 14, 2022 /PRNewswire/ -- Recently, China Medical System ("CMS", 0867.HK) announced its annual results. After recording continuous performance growth in the difficult time of the pandemic in 2020, it once again achieved a new record high, with revenue ofRMB 8,337 million, up 20.0%...

2022-04-14 20:24 1616

Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control

SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co....

2022-04-14 19:45 2519

Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control

First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent

Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American men, after lung cance...

2022-04-14 19:00 2471

Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/LAG-3...

2022-04-14 15:39 1951

Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/CD73 ...

2022-04-14 15:05 1748

Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...

2022-04-14 14:54 1958

Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment

SAN FRANCISCO and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...

2022-04-14 08:30 5649

AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

SUZHOU, China and ROCKVILLE, Md., April 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has presented the latest results from six...

2022-04-14 08:28 1987

TauRx's late-stage clinical trial reaches new milestone

- Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's ABERDEEN, Scotland and SINGAPORE, April 14, 2022 /PRNewswire/ -...

2022-04-14 08:17 1977

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW004, an oral tablet formulation of its Proprietary GLP-1 Analogue (Ecnoglutide)

HANGZHOU, China and SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of subject dosing in its Phase 1 clinic...

2022-04-14 08:00 2129

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer

NANJING, China, April 13, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN0018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib...

2022-04-14 08:00 2041

Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders

Insilico Medicine Nominates Its USP1 Small Molecule Inhibitor as a Preclinical Candidate for Tumors with Homologous Recombination Deficiency NEW YORK, April 13, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery com...

2022-04-13 23:00 3169

European Wellness Signs MOU in Dubai Expo 2020 to Strengthen Medical Tourism into Malaysia and Develop Advanced Biological Regenerative Medicine in UAE

DUBAI, UAE, April 13, 2022 /PRNewswire/ -- European Wellness Biomedical Group (EW Group), through its Malaysian subsidiary European Wellness Academie, and Dubai- based healthcare distribution and technology group, AK International LLC, have signed a Memorandum of Understanding (MOU) on 30th March ...

2022-04-13 21:38 3195

European Wellness Signs MOU in Dubai Expo 2020 to Strengthen Medical Tourism into Malaysia and Develop Advanced Biological Regenerative Medicine in UAE

Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland

HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Ascletis Pharmaceuticals Co., Ltd. ("Ascletis Pharmaceuticals") has signed an agreement with China Meheco International Co., Ltd. for distribution of its ritonavi...

2022-04-13 21:00 3147